RT Book, Section A1 Kim, Dae Won A1 Gershenwald, Jeffrey E. A1 Patel, Sapna P. A1 Davies, Michael A. A2 Kantarjian, Hagop M. A2 Wolff, Robert A. SR Print(0) ID 1126745074 T1 Melanoma T2 The MD Anderson Manual of Medical Oncology, 3e YR 2016 FD 2016 PB McGraw-Hill Medical PP New York, NY SN 9780071847940 LK accessmedicine.mhmedical.com/content.aspx?aid=1126745074 RD 2024/03/28 AB Melanoma is the most aggressive form of skin cancer. Although its incidence pales in comparison to basal cell carcinoma and squamous cell carcinoma (SCC), melanoma is the cause of approximately 75% of all skin cancer–related deaths. The majority of patients who are diagnosed with early-stage melanoma have very good outcomes with appropriate surgical management. In contrast, patients with regional and distant metastases have historically had poorer outcomes, because agents that have proven efficacious in other malignancies (eg, chemotherapy) generally have had limited activity in this disease. However, the management of melanoma is evolving rapidly due to parallel breakthroughs in the understanding and targeting of the molecular drivers of this disease and the regulators of the antitumor immune response. These advances are rapidly translating into improved outcomes in patients with advanced melanoma and the consideration of new diagnostic and therapeutic approaches across the full continuum of this disease.